MicroRNA‑101 suppresses colorectal cancer progression by negative regulation of Rap1b

Abstract

Colorectal cancer (CRC) is the fourth most lethal malignancy and is the second most common cause of cancer-associated mortality worldwide. The development of high-throughput sequencing has enabled the identification of potential biomarkers for the diagnosis and treatment of various types of cancer. Although microRNA-101 (miR-101) has been demonstrated to be a potential biomarker of CRC, its detailed mechanisms remain to be fully discovered. In the present study, overall survival analysis was applied to determine the association between miR-101 and CRC prognosis. Reverse transcription-quantitative PCR (RT-qPCR) was used to examine gene expression levels in tissues and cells. Cell proliferative and apoptotic activities were determined by MTT and flow cytometry assays, respectively. Wound healing and Transwell assays were used to examine CRC cell migration and invasion, respectively. In the present study, RT-qPCR analysis indicated that miR-101 was significantly downregulated in CRC tissues and cells. However, clinical data collected from The Cancer Genome Atlas revealed no significant association between the expression levels of miR-101 and the prognosis of CRC. Additionally, miR-101 inhibited the progression of CRC by directly binding to the 3'-untranslated region of Ras-related protein Rap1b (Rap1b). This was associated with downregulation of Rap1b expression. Furthermore, the overexpression of Rap1b promoted miR-101 mimic-attenuated CRC cell progression. The present study demonstrated that miR-101 may be involved in the repression of the CRC progression by forming a negative feedback loop with Rap1b. The findings revealed the interaction between miR-101 and Rap1b during the progression of CRC, which could aid the development of therapeutic strategies.

lncRNA DLEU2 Accelerates Oral Cancer Progression via miR-30a-5p/RAP1B Axis to Regulate p38 MAPK Signaling Pathway

“…These results suggest that si-DLEU2 exerts a tumor suppressor effect through the interaction with miR-30a-5p and RAP1B. Furthermore, the tumor suppressor effect of RAP1B on OC is consistent with its role in other cancers such as thyroid cancer [33] and colorectal cancer [34].…”

Prognostic and immunological role of Ras-related protein Rap1b in pan-cancer

“…In addition, Rap1b had been reported to be involved in the development and progression of a variety of malignant tumors. By inhibiting the expression of Rap1b, the proliferation and migration of hepatocellular carcinoma (HCC) [ 8 ], renal cell carcinoma (RCC) [ 9 ], esophageal squamous cell carcinoma (ESCC) [ 10 ], colorectal cancer cells (CRC) [ 11 ] and melanoma cells [ 12 ] had been inhibited. Moreover, downregulation of Rap1b inhibited the invasion of thyroid cancer (TC) and epithelial mesenchymal transformation (EMT) [ 13 , 14 ], whereas the autophagy and apoptosis in gastric cancer cell lines MKN-28 and SGC-7901 had been promoted [ 15 ].…”

miR-22-3p regulates hepatocellular carcinoma invasion and proliferation through the Rap1/mTOR signaling pathway

“…It regulates cell proliferation and differentiation, enhances endothelial cell adhesion and maintains integrity of vascular endothelial cells (Cui et al 2021;Mo, et al 2018;Zhou, et al 2020a). Rap1B is abnormally expressed in tumors and negatively regulated colon cancer (Zhou, et al 2020b), inhibited the thyroid cancer proliferation and invasion ) and promoted the progression of endometrial cancer (Yang, et al 2020). In HCC, Rap1B has only been reported to regulate invasion and migration (Tang, et al 2018).…”